NCT03641950View on ClinicalTrials.gov

The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.

PHASE4CompletedINTERVENTIONAL

Enrollment

249

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

May 31, 2015

Study Completion Date

January 7, 2016

Conditions

Essential Blepharospasm

Interventions

DRUG

Botulinum toxin type A

Recommended initial dose to be intra-muscularly injected to the medial and contralateral pretarsal orbicularis oculi of the upper eyelid and the contralateral pretarsal orbicularis oculi of the lower eyelid is 1.25-2.5U (0.05ml \~ 0.1ml per site).

Trial Locations (1)

06162

Hugel, Seoul

All Listed Sponsors

lead

Hugel

INDUSTRY

NCT03641950 - The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm. | Biotech Hunter | Biotech Hunter